{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:46:48Z","timestamp":1791406008559,"version":"4.3.3"},"reference-count":44,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T00:00:00Z","timestamp":1438646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Alisporivir (<jats:styled-content style=\"fixed-case\">ALV<\/jats:styled-content>) is an oral, host\u2010targeting agent with pangenotypic anti\u2010hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) activity and a high barrier to resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate efficacy and safety of <jats:styled-content style=\"fixed-case\">ALV<\/jats:styled-content> plus peginterferon\u2010\u03b12a and ribavirin (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>) in treatment\u2010na\u00efve patients with chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1 infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Double\u2010blind, randomised, placebo\u2010controlled, Phase 3 study evaluating <jats:styled-content style=\"fixed-case\">ALV<\/jats:styled-content> 600\u00a0mg once daily [response\u2010guided therapy (<jats:styled-content style=\"fixed-case\">RGT<\/jats:styled-content>) for 24 or 48\u00a0weeks or 48\u00a0weeks fixed duration] or <jats:styled-content style=\"fixed-case\">ALV<\/jats:styled-content> 400\u00a0mg twice daily <jats:styled-content style=\"fixed-case\">RGT<\/jats:styled-content> with <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>, compared to <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> alone. Following a Food and Drug Administration partial clinical hold, <jats:styled-content style=\"fixed-case\">ALV<\/jats:styled-content>\/placebo was discontinued and patients completed treatment with <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> only. At that time, 87% of patients had received \u226512\u00a0weeks and 20% had received \u226524\u00a0weeks of <jats:styled-content style=\"fixed-case\">ALV<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> triple therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1081 patients were randomised (12% cirrhosis, 55% <jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">TT <\/jats:styled-content><jats:italic><jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>28B<\/jats:italic>). Addition of <jats:styled-content style=\"fixed-case\">ALV<\/jats:styled-content> to <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> improved virological response in a dose\u2010dependent fashion. Overall, sustained virological response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12; primary endpoint) was 69% in all <jats:styled-content style=\"fixed-case\">ALV<\/jats:styled-content> groups vs. 53% in <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> control. Highest <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 (90%) was achieved in patients treated with <jats:styled-content style=\"fixed-case\">ALV<\/jats:styled-content> 400\u00a0mg twice daily and <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> for &gt;24\u00a0weeks. Seven cases of pancreatitis were reported, with similar frequency between <jats:styled-content style=\"fixed-case\">ALV<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> control groups (0.6% vs. 0.8% respectively). Adverse events seen more frequently with <jats:styled-content style=\"fixed-case\">ALV<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> than with <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> alone were anaemia, thrombocytopenia, hyperbilirubinaemia and hypertension.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Alisporivir, especially the 400\u00a0mg twice daily regimen, increased efficacy of <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> therapy in treatment\u2010na\u00efve patients with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1 infection. The mechanism of action and pangenotypic activity suggest that alisporivir could be useful in interferon\u2010free combination regimens.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.13342","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T07:49:00Z","timestamp":1438674540000},"page":"829-844","source":"Crossref","is-referenced-by-count":47,"title":["Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment\u2010na\u00efve patients with chronic <scp>HCV<\/scp> genotype 1 infection (<scp>ESSENTIAL II<\/scp>)"],"prefix":"10.1111","volume":"42","author":[{"given":"S.","family":"Zeuzem","sequence":"first","affiliation":[{"name":"Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Bialystok Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Vierling","sequence":"additional","affiliation":[{"name":"Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Mazur","sequence":"additional","affiliation":[{"name":"Chorz\u00f3w Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mazzella","sequence":"additional","affiliation":[{"name":"Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Thongsawat","sequence":"additional","affiliation":[{"name":"Chiang Mai Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Abdurakhmanov","sequence":"additional","affiliation":[{"name":"Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Van K\u00ednh","sequence":"additional","affiliation":[{"name":"Hanoi Viet Nam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Calistru","sequence":"additional","affiliation":[{"name":"Bucharest Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Heo","sequence":"additional","affiliation":[{"name":"Busan Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Stanciu","sequence":"additional","affiliation":[{"name":"Iasi Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gould","sequence":"additional","affiliation":[{"name":"Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Makara","sequence":"additional","affiliation":[{"name":"Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.\u2010J.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Yunlin County Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Buggisch","sequence":"additional","affiliation":[{"name":"Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Samuel","sequence":"additional","affiliation":[{"name":"Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mutimer","sequence":"additional","affiliation":[{"name":"Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Nault","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Merz","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Bao","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. H.","family":"Griffel","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brass","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. V.","family":"Naoumov","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ESSENTIAL II Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,8,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"e_1_2_7_3_1","unstructured":"World Health Organization.Hepatitis C. Fact sheet N\u00b0164. April 2014. Available at:http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/(accessed February 2015)."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3308"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7085"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13096"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13085"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13090"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12764"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S30946"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00016-14"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.008"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi1003266"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22835"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12360"},{"issue":"4","key":"e_1_2_7_19_1","first-page":"309A","article-title":"Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)\u2010free or IFN\u2010add\u2010on regimen in treatment\u2010na\u00efve patients with HCV GT2 or GT3: final results from the VITAL\u20101 study","volume":"56","author":"Pawlotsky JM","year":"2012","journal-title":"Hepatology"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.039"},{"key":"e_1_2_7_21_1","unstructured":"GuoT GelperinK SeniorJ.A tool to help you decide (detect potentially serious liver injury). March 2008. Available at:http:\/\/www.fda.gov\/downloads\/Drugs\/ScienceResearch\/ResearchAreas\/ucm076777.pdf(accessed June 2015)."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/11586600-000000000-00000"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261982"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60494-3"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60538-9"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01263.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013687"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01236-09"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00919-12"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60823-5"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:DDAS.0000034562.17003.50"},{"key":"e_1_2_7_34_1","article-title":"Acute pancreatitis during interferon\u2010alpha and ribavirin treatment for hepatitis C","author":"da Sila J","year":"2009","journal-title":"BMJ Case Rep"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000256557"},{"key":"e_1_2_7_36_1","unstructured":"Pharmacist's Letter\/Prescriber's Letter. Drug\u2010induced pancreatitis. April 2013.http:\/\/pharmacistsletter.therapeuticresearch.com\/pl\/ArticleDD.aspx?nidchk=1&cs=&s=PL&pt=2&fpt=2&dd=290403(accessed June 2015)."},{"key":"e_1_2_7_37_1","first-page":"1413","article-title":"Does hepatitis C (Hep C) and\/or interferon (IFN) increase acute pancreatitis (AP) risk?","volume":"41","author":"Whitcomb D","year":"2012","journal-title":"Pancreas"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2576-2"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2014.03.008"},{"key":"e_1_2_7_40_1","first-page":"269","article-title":"[Possible telaprevir\u2010induced pancreatitis. A case study]","volume":"37","author":"Selvi Sabater P","year":"2013","journal-title":"Farm Hosp"},{"key":"e_1_2_7_41_1","first-page":"1997","article-title":"A case of chronic hepatitis C with pancreas divisum and acute pancreatitis during combination treatment with telaprevir\/peginterferon\/ribavirin","volume":"111","author":"Morio R","year":"2014","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.109309"},{"key":"e_1_2_7_43_1","unstructured":"FleischerR.NDA 201\u2010917. Telaprevir. Clinical Review. April 2011. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/201917Orig1s000MedR.pdf(accessed June 2015)."},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25514"},{"issue":"1","key":"e_1_2_7_45_1","first-page":"436A","article-title":"Alisporivir treatment does not cause or exacerbate pancreatitis when co\u2010administered with interferon\u2010alpha and\/or ribavirin in the cerulein\u2010induced pancreatitis rat model","volume":"58","author":"Brees D","year":"2013","journal-title":"Hepatology"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13342","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13342","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:00:17Z","timestamp":1694430017000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,4]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/apt.13342"],"URL":"https:\/\/doi.org\/10.1111\/apt.13342","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,4]]}}}